Oxaliplatin-induced hyperexcitability syndrome in a patient with pancreatic cancer

Journal of the Pancreas

Volumn 10, Issue 4, 2009, Pages 459-461

  Saadati, Hamid ^a   Saif, Muhammad Wasif ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypersensitivity; Isaacs syndrome; Oxaliplatin; Pancreatic neoplasms

Indexed keywords

CAPECITABINE; DIPHENHYDRAMINE; GEMCITABINE; GLUCONATE CALCIUM; MAGNESIUM SULFATE; OXALIPLATIN; PANITUMUMAB; PREGABALIN;

ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CASE REPORT; EATING; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; HYPEREXCITABILITY SYNDROME; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MYOFASCIAL PAIN; MYOKYMIA; OBSTRUCTIVE JAUNDICE; PANCREAS; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; POSITRON EMISSION TOMOGRAPHY; TREATMENT RESPONSE;

ADULT; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; ISAACS SYNDROME; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS;

EID: 68649117449     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005; 1:249-58.
2. Saif MW, Hashmi S. Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemother Pharmacol 2008; 61:349-54.
3. Lahrmann H, Albrecht G, Drlicek M, Oberndorfer S, Urbanits S, Wanschitz J, et al. Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin's disease. Muscle Nerve 2001; 24:834-8.
4. Forte F, Pretegiani E, Battisti C, Sicurelli F, Federico A. Neuromyotonia as paraneoplastic manifestation of bladder carcinoma. J Neurol Sci 2009; 280: 111-112.
5. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29(5 Suppl. 15):21-33.
6. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005; 5:116.
7. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004; 29:387-92.
8. Bostock H, Burke D, Hales JP. Differences in behaviour of sensory and motor axons following release of ischaemia. Brain 1994; 117:225-34.
9. Auger RG. AAEM minimonograph No.44: diseases associated with excess motor unit activity. Muscle Nerve 1994; 17:1250-63.
10. Zielasek J, Martini R, Suter U, Toyka KV. Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve 2000; 23:696-701.
11. Reeback J, Benton S, Swash M, Schwartz MS. Penicillamine-induced neuromyotonia. Br Med J 1979; 1:1464-5.
12. Caldron PH, Wilbourn AJ. Gold neurotoxicity and myokymia. J Rheumatol 1988; 15:528-9.
13. Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O, et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997; 41:238-46.
14. Nagado T, Arimura K, Sonoda Y, Kurono A, Horikiri Y, Kameyama A, et al. Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 1999; 122:2057-66.
15. Maddison P, Newsom-Davis J, Mills KR Strength-duration properties of peripheral nerve in acquired neuromyotonia. Muscle Nerve 1999; 22:823-30.
16. Mariani G, Garrone O, Granetto C, Numico G, LaCiura P, Grecchi G, et al. Oxaliplatin-induced neuropathy: could gabapentin be the answer? Proc Am Soc Clin Oncol 2000; 19:609, Abstract 2397.
17. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003; 105:133-41.
18. Frampton JE, Foster RH. Pregabalin in the treatment of postherpetic neuralgia. Drugs 2005; 65:111-20.
19. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005; 115:254-63.
20. Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, et al. Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006; 6:146-51.